Abcam, ab320832, Anti-STT3A antibody [EPR29178-10] - BSA and Azide free

Size: 100µg / 1mg
Knockout Tested Rabbit Recombinant Monoclonal STT3A antibody. Carrier free. Suitable for WB, Dot, IP and reacts with Human, Mouse, Synthetic peptide - Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR29178-10,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse,
Applications:Dot, WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab320832 is the carrier-free version of
ab320831
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: 100% PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
STT3A also known as oligosaccharyltransferase 48 kDa subunit plays an important role in the enzymatic process of N-glycosylation specifically as a catalytic subunit in the oligosaccharyltransferase (OST) complex. This protein has a mass of approximately 48 kDa. STT3A is expressed predominantly in rough endoplasmic reticulum membranes where it contributes to the transfer of oligosaccharides onto nascent polypeptide chains a critical step for protein maturation and function.
Biological function summary
STT3A is part of the OST complex which catalyzes the transfer of glycan from a lipid donor to asparagine residues on nascent polypeptides in a process known as co-translational N-glycosylation. This modification is essential for proper protein folding stability and activity. The OST complex with STT3A as a catalytic core is fundamental in eukaryotic cells affecting the function of numerous glycoproteins. It interacts with various components within the endoplasmic reticulum to ensure efficient glycosylation.
Pathways
The involvement of STT3A extends to the protein processing in endoplasmic reticulum pathway and is integral to the broader process of protein folding and quality control. This pathway ensures proper protein configuration and prevents the accumulation of misfolded proteins. STT3A functionally relates to proteins like calnexin and calreticulin which work in the calnexin/calreticulin cycle to assist in the folding of glycoproteins indicating its important role in maintaining protein homeostasis in cells.
Defects or dysregulation of STT3A have associations with congenital disorders of glycosylation (CDG) a group of rare inherited metabolic disorders affecting glycoprotein synthesis. Anomalies in STT3A activity can disrupt normal glycoprotein functions leading to a wide range of symptoms including developmental delays and neurological issues. Moreover STT3A dysfunction has connections with cancer progression as altered N-glycosylation patterns are frequently observed in tumor cells affecting proteins such as EGFR and HER2 which are often targets in oncogenesis.